论文部分内容阅读
目的探讨血清促红细胞生成素(erythropoietin,EPO)、可溶性转铁蛋白受体(soluble transferrin receptor,sTfR)水平和癌性贫血之间的关系,为临床合理使用重组人红细胞生成素(Recombinant Human Erythropietin,r-HuEPO)和铁剂治疗癌性贫血提供理论依据。方法采用酶联免疫分析方法(ELISA)测定60例癌性贫血患者血清EPO水平和sTfR水平,并将其与52例非癌性贫血患者的测定值及20例正常对照进行比较,以直线相关分析sTfR、EPO水平和Hb之间的关系。结果癌性贫血患者血清EPO、sTfR均较正常对照显著升高(P<0.01);癌性贫血患者血清EPO显著高于非癌性贫血患者(P<0.05);癌性贫血患者sTfR高于非癌性贫血患者,差异无显著性(P>0.05);癌性贫血患者血清EPO、sTfR升高的程度与贫血严重程度一致,与Hb值存在负相关,但与病期无明显相关性;EPO和sTfR之间无相关性。结论恶性肿瘤患者的血清EPO和sTfR水平能较好地反映其贫血病因,对贫血的治疗以及预后判断有一定的临床参考价值。
Objective To investigate the relationship between the levels of serum erythropoietin (EPO), soluble transferrin receptor (sTfR) and cancerous anemia in order to make rational use of recombinant human erythropoietin r-HuEPO) and iron treatment of cancer anemia provide a theoretical basis. Methods Serum levels of EPO and sTfR in 60 patients with cancerous anemia were measured by enzyme-linked immunosorbent assay (ELISA). The serum EPO level and sTfR level were compared with those of 52 non-cancerous anemia patients and 20 normal controls. The linear correlation analysis sTfR, EPO levels and Hb. Results The serum levels of EPO and sTfR in patients with cancerous anemia were significantly higher than those in controls (P <0.01). The serum levels of EPO in patients with cancerous anemia were significantly higher than those in patients with non-cancerous anemia (P <0.05) (P> 0.05). The levels of serum EPO and sTfR in patients with cancerous anemia were consistent with the severity of anemia, but negatively correlated with Hb, but no significant correlation with the stage of disease There was no correlation between sTfR and sTfR. Conclusions Serum levels of EPO and sTfR in patients with malignant tumors can better reflect the cause of anemia and have certain clinical value for the treatment of anemia and prognosis.